Potent acyl-CoA synthetase 10 inhibitors kill Plasmodium falciparum by disrupting triglyceride formation

Autor: Selina Bopp, Charisse Flerida A. Pasaje, Robert L. Summers, Pamela Magistrado-Coxen, Kyra A. Schindler, Victoriano Corpas-Lopez, Tomas Yeo, Sachel Mok, Sumanta Dey, Sebastian Smick, Armiyaw S. Nasamu, Allison R. Demas, Rachel Milne, Natalie Wiedemar, Victoria Corey, Maria De Gracia Gomez-Lorenzo, Virginia Franco, Angela M. Early, Amanda K. Lukens, Danny Milner, Jeremy Furtado, Francisco-Javier Gamo, Elizabeth A. Winzeler, Sarah K. Volkman, Maëlle Duffey, Benoît Laleu, David A. Fidock, Susan Wyllie, Jacquin C. Niles, Dyann F. Wirth

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)

Drug resistance to current antimalarials is rising and new drugs and targets are urgently needed. Here the authors identify Plasmodium falciparum acyl-CoA synthetase 10 as a new target whose inhibition leads to a decrease in triacylglycerols.

Externí odkaz: https://doaj.org/article/8ae40ec50bdc468aaa960a15e9ca87b3

The most abundant cyst wall proteins of Acanthamoeba castellanii are lectins that bind cellulose and localize to distinct structures in developing and mature cyst walls.

Autor: Pamela Magistrado-Coxen, Yousuf Aqeel, Angelo Lopez, John R Haserick, Breeanna R Urbanowicz, Catherine E Costello, John Samuelson

Publikováno v: PLoS Neglected Tropical Diseases, Vol 13, Iss 5, p e0007352 (2019)

BackgroundAcanthamoeba castellanii, which causes keratitis and blindness in under-resourced countries, is an emerging pathogen worldwide, because of its association with contact lens use. The wall makes cysts resistant to sterilizing reagents in lens

Externí odkaz: https://doaj.org/article/614497fdf9cd46d5ac998e60b7f4b006

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

424P Micro-dystrophin expression and safety with delandistrogene moxeparvovec gene therapy for DMD in a broad population: phase 1B trial (ENDEAVOR).

Autor: Proud, C.¹ (AUTHOR), Zaidman, C.² (AUTHOR), McDonald, C.³ (AUTHOR), Day, J.⁴ (AUTHOR), Thrasher, P.⁵ (AUTHOR), Asher, D.⁵ (AUTHOR), Murphy, A.⁶ (AUTHOR), Guridi, M.⁷ (AUTHOR), Ding, K.⁵ (AUTHOR), Reid, C.⁶ (AUTHOR), Lewis, S.⁵ (AUTHOR), Magistrado-Coxen, P.⁵ (AUTHOR), Palatinsky, E.⁵ (AUTHOR), Wandel, C.⁷ (AUTHOR), Potter, R.⁵ (AUTHOR), Rodino-Klapac, L.⁵ (AUTHOR), Mendell, J.^8,9 (AUTHOR)

Publikováno v: Neuromuscular Disorders. 2024 Supplement 1, Vol. 43, pN.PAG-N.PAG. 1p.